TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusions:~* Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as defined in the GINA Guidelines) which is unlikely to exacerbate during the study (e.g., due to seasonal allergen exposure).~* Patients must be on a stable dose of Inhaled Corticosteroids (ICS) for at least 30 days prior to Visit 1. Patients on a combination of ICS/LABA must discontinue the use of LABA and must be on a stable dose of ICS for 30 days prior to Visit 1.~* Qualifying spirometry at Visit 1 demonstrates highest FEV1 is ≤ 85% and ≥ 60% of predicted for age, height, and gender using NHANES III (NHANES 2010) when bronchodilator medications have been withheld the appropriate length of time per the List of Concomitant Medications (Appendix III)~* Patient demonstrates reversibility with an increase in FEV1 of 12% and 200 mL after the administration of 360 µg of albuterol.~* Highest pre-dose FEV1 at Visits 2, 4, 6, 8, and 10 must be within 25% of the qualifying FEV1 at Visit 1~Exclusions:~* Patients with any clinically significant respiratory conditions other than mild to moderate asthma, such as COPD, active tuberculosis, or history of interstitial lung disease~* Patients with a severe asthma exacerbation requiring hospitalization in the previous 12 months~* Patient is not able to withhold use of inhaled short-acting beta-agonist (SABA) for at least 6 hours prior to visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental 1 (Type: EXPERIMENTAL): Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
- Experimental 2 (Type: EXPERIMENTAL): Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): Foradil Aerolizer, Low Dose
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): Foradil Aerolizer, High Dose
- Placebo (Type: PLACEBO_COMPARATOR): Dose matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years or older~2. Diagnosis of fibromyalgia~3. Clinically significant sleep disturbance, defined as difficulty in maintaining sleep (wake after sleep onset and arousal index) at least three times per week for at least one month~4. Understand and willing to cooperate with the study procedures~5. Maintain a normal sleep schedule, with daytime-awake and nighttime-sleep schedule, with customary bedtime between 9 PM and midnight, and rise time 5 AM and 9 AM~6. Patients who are able to speak, read, and understand English language and able to follow the study protocol, and are able to sign the informed consent~Exclusion Criteria:~1. Subject has any of the following medical conditions:~   Liver disease, blood disorder, autoimmune disease, endocrine, cardiovascular, hypertension, renal, hepatic, gastrointestinal, or neurological disorder, active peptic ulcer or inflammatory bowel disease~2. Significant sleep apnea~3. Periodic leg movement disorder (PLMD) or restless legs syndrome (RLS)~4. Any form of severe psychiatric illness, moderate to severe depression, including significant risk of suicide~5. Patients with uncontrolled glaucoma~6. Inability to discontinue the prohibited medications~7. Female of childbearing potential not using birth control measures; or lactating.~8. History of alcohol, narcotic, benzodiazepines or other substance abuse within the past one year.~9. Patient on prohibited medication will include but not limited to:~   * Anxiolytics, anti-convulsants, antipsychotics, lithium, barbiturates, anti-histamines, monoamine oxidase inhibitors, or medications that affect sleep~  * Any prescription or over the counter stimulants~  * Medications that are contraindicated with the use of milnacipran~10. Excessive caffeine use, defined as a consumption of more than 500 mg of caffeine or other xanthines, smoking \>1/2 a pack/day or alcohol use \>14 units/week~11. History of allergy to milnacipran.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- milnacipran (Type: EXPERIMENTAL): Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
- placebo (Type: PLACEBO_COMPARATOR): Drug: placebo 45-day placebo treatment before or after crossover to milnacipran

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Visual impairment due to CNV secondary to PM.~* Best corrected visual acuity in the study eye \> 24 and \< 78 ETDRS letters.~* High myopia (\> -6D),~* anterio-posterior elongation \> 26 mm; posterior changes compatible with the pathologic myopia.~* Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.~Exclusion Criteria:~* Some preexisting eye disorders or systemic diseases;-Blood pressure \> 150/90 mmHg~* Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF or verteporfin PDT in the study eye~* Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): 0.5 mg ranibizumab driven by visual acuity stability criteria
- Group II (Type: EXPERIMENTAL): 0.5 mg ranibizumab driven by disease activity criteria
- Group III (Type: ACTIVE_COMPARATOR): verteporfin PDT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Standard-risk of recipients with hematological malignancies (including AML-CR1, ALL-CR1, CML-CP, MDS-RA, RARS,RCMD,RAEB-1); age from 40 to 60; having HLA-matched sibling donor; Eastern Cooperative Oncology Group (ECOG)≤1, ejection fraction (EF)≥50%; bilirubin≤35µmol/L; AST, and ALT lower than or equall to two-fold baseline;creatinie≤130µmol/L.~Exclusion Criteria:~* Active, uncontrolled infection; severe allergy to ATG, including shock or laryngeal edema; secondary stem cell transplant recipient; haplidentical recipients; matched unrelated donor recipients; non-myeloablative condioning regimen recipients; EF\<50%; bilirubin\>35µmol/L; AST, and ALT higher than two-fold baseline; creatinie\>130µmol/L.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- routine prophylaxis (Type: ACTIVE_COMPARATOR): In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
- ATG prophylaxis (Type: EXPERIMENTAL): In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Member of the Monroe Plan for Medical Care (managed care organization)~* Patient of a participating practice~* Ages 10.75 to \<18 years of age~Exclusion Criteria:~* Member of the Monroe Plan for Medical care for less than 6 months~* ICD-9 diagnosis of 999.4 for anaphylactic reaction to a vaccine or its components.~* Encephalopathy within 7 days of a previous dose of a pertussis containing vaccine not attributable to another identifiable cause~* Guillain-Barre- ICD-9 code is 357.0

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Autodialer (Type: EXPERIMENTAL): Autodialer reminder/recall
- Letters (Type: EXPERIMENTAL): Mailed reminder letters
- Controls (Type: NO_INTERVENTION): Controls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Acute appendicitis where surgery is planned. Diagnosis of appendicitis should be verified either by clinical diagnosis with Adult Appendicitis Score \>=16 or by diagnostic imaging (CT-scan, MRI or ultrasound) showing appendicitis. All patients with symptoms at least 3 days should undergo diagnostic imaging before inclusion.~Exclusion Criteria:~* Complicated appendicitis according to diagnostic imaging. The following findings indicate complicated appendicitis: extraluminal air or extraluminal fecalith; fluid collection, abscess or phlegmon next to appendix; non-enhancement appendiceal wall on contrast enhanced CT-scan.~* Plasma C-reactive protein \>=100~* Fever measured on emergency department over 38.5 degrees Celcius.~* Clinical generalized peritonitis or other reason that indicate immediate surgery~* Pregnancy, pregnancy test is taken from all fertile aged women before randomization~* Allergy to study antibiotics, or anaphylactic reaction after betalactam antibiotic or other contraindication for metronidazole or ongoing antibiotic treatment or patient is carrier of resistant bacteria. (This exclusion criteria are applicable only on randomization into antibiotic treatment arms)~* Missing written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery within 8 hours, no antibiotics (Type: ACTIVE_COMPARATOR): Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
- Surgery within 24 hours, no antibiotics (Type: EXPERIMENTAL): Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
- Surgery within 8 hours, antibiotics (Type: EXPERIMENTAL): Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
- Surgery within 24 hours, antibiotics (Type: EXPERIMENTAL): Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented Paroxysmal Atrial Fibrillation (PAF): PAF diagnosis, 2 episodes of PAF within the last 2 months, at least 1 episode of PAF must be documented~* Age 18-75~* Documented Effectiveness Failure of one (1) AF drug~* Willing to be randomized to either group and do full 12 month follow-up~* Able to follow standardized AF drug protocol~Exclusion Criteria:~* Any cardioversion within 3 months or more than 2 within 2 years~* Amiodarone within 6 months~* LA size \> 5.0cm~* Previous LA ablation/surgery, structural heart disease, heart failure class III or IV~* Hypertrophic cardiomyopathy, Mitral prosthesis~* Unstable angina, uncontrolled hyperthyroidism~* Stroke or TIA within 6 months, MI within 2 months, cardiac surgery within 3 months~* Thrombocytosis, thrombocytopenia~* Any condition contraindicating chronic anticoagulation~* EF \<40%~* Pregnancy~* Life expectancy \<1year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
- Control (Type: ACTIVE_COMPARATOR): Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: US Phase III Study of APD421 in PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure and expected to require at least one overnight stay in hospital~Exclusion Criteria:~* Patients scheduled for outpatient/day case surgery~* Patients scheduled to undergo intra-thoracic, transplant or central nervous system surgery~* Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block~* Patients who are expected to remain ventilated for a period after surgery~* Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APD421 (Type: EXPERIMENTAL): APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants legally competent to sign and give informed consent and if appropriate assent as required by local laws~* Males and females ages 2 years and older (inclusive)~* Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for children) as determined by the Investigator~* Females of childbearing potential (FOCBP) must have a negative pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.~* In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.~* Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.~Exclusion Criteria:~* Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.~* Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~* Previous treatment with ARQ-151 or its active ingredient~* Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.~* Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product~* Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rofumilast Cream 0.3% (Type: EXPERIMENTAL): Participants receive roflumilast cream 0.3% once daily for 8 weeks.
- Vehicle cream (Type: PLACEBO_COMPARATOR): Participants receive vehicle cream once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
KEY INCLUSION CRITERIA:~1. Have completed all scheduled visits up to and including Visit 8 in the E2007-A001-206 (NCT00144690) study or Visit 9 of the E2007-G000-208 (NCT00416195) study.~2. Are reliable and willing to make themselves available for the study period and are able to record seizures and report adverse events themselves or have a caregiver who can record and report the events.~3. Females of childbearing potential must continue practicing a medically acceptable method of contraception (e.g., abstinence, a barrier method plus spermicide, or Intrauterine device (IUD)) and for 8 weeks after the end of the OLE study. Those women using hormonal contraceptives must also continue using an additional approved method of contraception (e.g., a barrier method plus spermicide, or IUD).~4. Are between the ages of 18 and 70 years of age, inclusive.~5. Are at least 40 kg (88 lb) of weight.~6. Are currently being treated with a stable dose of one, or a maximum of three licensed Anti-epileptic drugs (AEDs) and are known to take their medication(s) as directed.~KEY EXCLUSION CRITERIA:~1. Show evidence of clinically significant disease (cardiac, respiratory, gastrointestinal, renal disease, etc.,) that, in the opinion of the Investigator(s), could affect the participant's safety or trial conduct.~2. Show evidence of significant active hepatic disease and/or bilirubin greater than 1.5 mg/dL. Stable elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) due to concomitant medication(s) will be allowed if they are less than two times the upper limit of normal (ULN).~3. Show evidence of significant active hematological disease. White blood cell (WBC) count cannot be less than or equal to 2500/microL or an absolute neutrophil count less than or equal to 1000/microL.~4. Clinically significant ECG abnormality, including prolonged QTc (defined as greater than or equal to 450 msec).~5. Presence of major active psychiatric disease. Participants taking a stable dose of selective serotonin reuptake inhibitor (SSRI) antidepressant will be allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of ABI-007 for Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed gastric adenocarcinoma~* Received one prior regimen containing fluoropyrimidine analogs and developed disease progression or recurrence~* Age: 20 - 74~* At least one measurable lesion by RECIST criteria~Exclusion Criteria:~* History of Taxans use~* Patients with another active malignancy~* Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE)~* Chronic treatment with steroids

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ABI-007

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete